Wuhan Hiteck Biological Pharma Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 19.96%

Wuhan Hiteck Biological Pharma Co Ltd (300683) has an Asset Resilience Ratio of 19.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Wuhan Hiteck Biological Pharma Co Ltd (300683) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥526.22 Million

≈ $77.00 Million USD Cash + Short-term Investments

Total Assets

CN¥2.64 Billion

≈ $385.87 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Asset Resilience Ratio has changed over time. See 300683 total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Wuhan Hiteck Biological Pharma Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Wuhan Hiteck Biological Pharma Co Ltd (300683) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥526.22 Million	19.96%
Total Liquid Assets	CN¥526.22 Million	19.96%

Asset Resilience Insights

Good Liquidity Position: Wuhan Hiteck Biological Pharma Co Ltd maintains a healthy 19.96% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Wuhan Hiteck Biological Pharma Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wuhan Hiteck Biological Pharma Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tasly Pharmaceutical Group Co Ltd SHG:600535	Drug Manufacturers - Specialty & Generic	9.09%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.02%
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	Drug Manufacturers - Specialty & Generic	0.01%
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	Drug Manufacturers - Specialty & Generic	26.36%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%

Annual Asset Resilience Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Wuhan Hiteck Biological Pharma Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	15.31%	CN¥449.69 Million ≈ $65.80 Million	CN¥2.94 Billion ≈ $429.72 Million	+15.30pp
2023-12-31	0.01%	CN¥303.97K ≈ $44.48K	CN¥2.97 Billion ≈ $434.79 Million	-5.31pp
2022-12-31	5.32%	CN¥144.04 Million ≈ $21.08 Million	CN¥2.71 Billion ≈ $396.03 Million	-13.75pp
2021-12-31	19.07%	CN¥514.40 Million ≈ $75.27 Million	CN¥2.70 Billion ≈ $394.73 Million	+7.62pp
2020-12-31	11.45%	CN¥250.39 Million ≈ $36.64 Million	CN¥2.19 Billion ≈ $319.96 Million	-10.65pp
2019-12-31	22.11%	CN¥479.57 Million ≈ $70.18 Million	CN¥2.17 Billion ≈ $317.47 Million	--

pp = percentage points

About Wuhan Hiteck Biological Pharma Co Ltd

SHE:300683 China Drug Manufacturers - Specialty & Generic

Market Cap

$676.90 Million

CN¥4.63 Billion CNY

Market Cap Rank

#11014 Global

#3267 in China

Share Price

CN¥35.34

Change (1 day)

+0.26%

52-Week Range

CN¥22.83 - CN¥59.56

All Time High

CN¥84.19